RUOResearch Use Only · Not FDA-cleared

Women's Complete
Hormonal Health

Endometriosis · PCOS · Osteoporosis · Menopause timing. Four GWAS-backed panels. Built for the most underserved population in consumer genomics. The only product of its kind in the DTC market.

⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.

📄
Download a sample report

See a fully rendered example — real RSIDs, peer-reviewed citations, and clinical action guidance — before you commit.

↓ Download sample
Key variants

RSIDs analyzed in this panel

Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.

rs7521902A/G
WNT4 · Endometriosis (p=1.8×10⁻¹⁵)
Risk allele — WNT pathway disruption
rs13394619A
GREB1 · Endometriosis hormonal pathway
Estrogen-responsive locus — proliferation risk
rs4870061T
LRP5 · Peak bone mineral density
Reduced Wnt/LRP5 signaling — lower peak BMD
rs16991615G
MCM8 · Age at natural menopause
G allele — later onset predicted (52–54 yrs)
Evidence base

Supporting literature

Nyholt et al. Nature Genetics 2012 (endometriosis · 4,604 cases · rs7521902 p=1.8×10⁻¹⁵). Mortlock et al. Human Reproduction Update 2014 (8 GWAS datasets · 17,045 cases). Day et al. Nature Genetics 2015 (PCOS). Estrada et al. Nature Genetics 2012 (56 BMD loci · n=32,961). Stolk et al. Nature Genetics 2012 (13 menopause loci).

Why women need their own genomics panel

Most PRS models were built primarily on UK Biobank data — which skews 94% white British and historically male-heavy. Conditions that affect only women (endometriosis, PCOS) were dramatically underpowered in genomics research for decades. Endometriosis takes an average of 7–10 years to diagnose from symptom onset. Genetic data will not replace that process — but it can accelerate it.

How these four findings interact

Endometriosis and PCOS share overlapping WNT pathway and metabolic genetics. Osteoporosis risk is directly modulated by your predicted estrogen exposure window — which is why the menopause timing panel is essential context for the bone density panel. These four conditions are not independent. AuraGen presents them as an integrated hormonal health narrative.

⚠ Research Use Only (RUO)

This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com

✦ AuraGen Exclusive · Add-On
$99
Instant unlock · no new kit required
  • Endometriosis PRS — WNT4, GREB1, CDKN2B-AS1, 7p15.2 locus (Nature Genetics 2012)
  • PCOS PRS — LHCGR, THADA, DENND1A pathway (Day et al. Nature Genetics 2015)
  • Osteoporosis / BMD PRS — LRP5, ESR1, RANKL/OPG pathway (Estrada et al. 2012)
  • Predicted age at natural menopause — MCM8, BRSK1, UIMC1 (Stolk et al. 2012)
  • Cross-panel hormonal health narrative — four conditions as one integrated story
  • Gynecologist-ready summary for clinical consultation included
Unlock this panel →↓ Download sample report

⚠ Research Use Only · Not FDA cleared